trending Market Intelligence /marketintelligence/en/news-insights/trending/acowhar7xtzketmvmwt5ga2 content esgSubNav
In This List

Therapure Biopharma's biologics unit plans IPO

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Therapure Biopharma's biologics unit plans IPO

Therapure Biopharma Inc..'s biologics division, Evolve Biologics, confidentially submitted a draft registration statement for an IPO in the U.S.

The IPO is expected to commence after the U.S. Securities and Exchange Commission completes its review process, subject to market and other conditions.

The Mississauga, Canada-based privately held company's biologics unit separates proteins from blood's plasma for use in treating diseases.